Market Overview

UPDATE: Dawson James Initiates Galena Biopharma at Market Outperform

Related GALE
Midday Gainers From Wednesday, August 27
UPDATE: MLV & Co Reiterates On Galena Biopharma On Positive Long-Term Outlook

Dawson James initiated coverage on Galena Biopharma (NASDAQ: GALE) with a Buy rating and a $3 price target.

Dawson James commented, "We believe investors have yet to fully appreciate NeuVax's clinical potential and chance of success in the Phase III PRESENT study currently underway. After assessing the NeuVax Phase II data on hand and speaking with Company management, we believe Galena has managed to implement several key insights gained from prior trials into in the Phase III PRESENT study, ignificantly improving its likelihood of success."

Galena Biopharma closed at $1.68 on Monday.

Latest Ratings for GALE

DateFirmActionFromTo
Mar 2014McNicoll Lewis VlakMaintainsBuy
Feb 2014Cantor FitzgeraldDowngradesBuySell
Nov 2013OppenheimerInitiates Coverage onOutperform

View More Analyst Ratings for GALE
View the Latest Analyst Ratings

Posted-In: Dawson James iAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (GALE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters